Filter Applied: multiple sclerosis,treatment of (Click to remove)
Relapse in Multiple Sclerosis
BMJ 350:h1765, Galea, I.,et al, 2015
Oral Versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients with Multiple Sclerosis (COPOUSEP):A Randomised, Controlled, Double-Blind,Non-Inferiority Trial
Lancet 386:974-981, LePage,E.,et al, 2015
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Tumefactive Demyelination: An Approach to Diagnosis and Management
JNNP 84:1047-1053, Hardy, T.A. & Chataway, J., 2009
The Bioavailability of IV Methylprednisolone and Oral Prednisone in Multiple Sclerosis
Neurol 63:1079-1080, Morrow,S.A.,et al, 2004
IV Immunoglobulins as Add-on Treatment to Methylprednisolone for Acute Relapses in MS
Neurol 63:2028-2033, Sorensen,P.S.,et al, 2004
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Gastric Tolerance of High-Dose Pulse Oral Prednisone in Multiple Sclerosis
Neurol 53:2093-2096, Metz,L.M.,et al, 1999
Effect of Steroids on Gd-Enhancing Lesions Before & During Beta Interferon 1a Trtm in Relapsing Remitting MS
Neurol 50:403-406, Gasperini,C.,et al, 1998
Double-Blind, Randomized, Placebo-Controlled Study of Oral, High-Dose Methylprednisolone in Attacks of MS
Neurol 51:529-534, Sellebjerg,F.,et al, 1998
Randomized Trial Comparing Two Different High Doses of Methylprednisolone in MS, A Clinical and MRI Study
Neurol 50:1833-1836, Oliveri,R.L.,et al, 1998
Use of Corticosteroids in Multiple Sclerosis by Consultant Neurologists in the United Kingdom
JNNP 54:362-365, Tremlett,H.L.,et al, 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Amelioration of Flulike Symptoms at the Onset of Interferon B-1b Therapy in Multiple Sclerosis by Low-Dose Oral Steriods is Related to a Decrease in Interleukin-6 Induction
Ann Neurol 44:682-685, Martinez-Caceres,E.M.,et al, 1998
Current Immunotherapy in Multiple Sclerosis
Immunology and Cell Biology 76:55-64, Bashir,K.&Whitaker,J.N., 1998
Randomised Trial of Oral and Intravenous Methylprednisolone in Acute Relapses of Multiple Sclerosis
Lancet 349:902-906, 8931997., Barnes,D.,et al, 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Megadose Corticosteroids in Multiple Sclerosis
Neurol 44:1-4, Kupersmith,M.J.,et al, 1994
The Use of Brain Magnetic Resonance Imaging in Multiple Sclerosis
Arch Neurol 51:505-516, Goodkin,D.E.,et al, 1994
Oral Megadose Methylprednisolone Therapy in a Pt with Chronic Progressive MS
Neurol 43:230, Gucuyener,K.,et al, 1993
Methylprednisolone in Multiple Sclerosis:A Comparison of Oral with Intravenous Therapy at Equivalent High Dose
JNNP 56:1219-1220, Alam,S.M.,et al, 1993
A Correlative Triad of Gadolinium-DTPA MRI, EDSS, & CSF-MBP in Relapsing MS Treated with High-Dose Intravenous Methylprednisolone
Neurol 42:63-67, Barkhof,F.,et al, 1992
The Use of Immunosuppressive Agents in the Treatment of Multiple Sclerosis:A Critical Review
Neurol 41:980-985, Goodin,D.S., 1991
Consensus and Controversy in Neurologic Practice, The Case of Steroid Treatment in Multiple Sclerosis
Arch Neurol 46:322, Menken,M., 1989
Quantitative Magnetic Resonance Imaging in Multiple Sclerosis:The Effect of High Dose Intravenous Methylprednisolone
JNNP 52:14-17, Kesselring,J.,et al, 1989
A Referendum on Clinical Trial Research in Multiple Sclerosis:Opinion of Jekyll Island Workshop
Neurol 39:977-981, Noseworthy,J.H.,et al, 1989
Relative Efficacy of Intravenous Methylprednisolone and ACTH in the Treatment of Acute Relapse in MS
Neurol 39:969-971, Thompson,A.J.,et al, 1989
A Placebo-Controlled, Randomized, Clinical Trial of Azathioprine with & without Methylpred in MS
Neurol 39:1018-1026, Ellison,G.W.,et al, 1989
Immunotherapy of Multiple Sclerosis
Ann Neurol 23:211-223, Weiner,H.L.&Hafler,D.A., 1988
Methylprednisolone and Multiple Sclerosis
Arch Neurol 45:669-670, Compston,A., 1988
Dangers from Methylprednisolone Acetate Therapy by Intraspinal Injection
Arch Neurol 45:804-806, Nelson,D.A., 1988
A Double-Blind Controlled Trial of High Dose Methylprednisolone in Patients with MS:1. Clinical Effects
JNNP 50:511-516, Milligan,M.N.,et al, 1987
Steroid Therapy in Multiple Sclerosis, Point of View
Arch Neurol 44:803-807, Troiano,R.,et al, 1987
Intravenous Methylprednisolone for Multiple Sclerosis in Relapse
JNNP 48:157-159, Barnes,M.P.,et al, 1985
Anaphylactoid Reaction to Methylprednisolone Pulsed Therapy for Multiple Sclerosis
Neurol 34:1119-1121, Pryse-Phillips,W.E.,et al, 1984
Treatment of Acute Exacerbations of Multiple Sclerosis with Intravenous Methylprednisone
JNNP 45:179-186, Buckley,C.,et al, 1982
Intraspinal Steroid Therapy
Neurol 31:168-171, Bernat,J.L., 1981
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975
Complications from Intrathecal Steroid Therapy in Patients with MS
Neurol 22:454, Nelson,D.,et al, 1972
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017